Gail Farfel
Direttore/Membro del Consiglio presso DURECT CORPORATION
Patrimonio netto: 116 784 $ in data 30/04/2024
Posizioni attive di Gail Farfel
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DURECT CORPORATION | Direttore/Membro del Consiglio | 25/04/2019 | - |
| Independent Dir/Board Member | 25/04/2019 | - | |
| AVROBIO, INC. | Direttore/Membro del Consiglio | 21/10/2020 | - |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Direttore/Membro del Consiglio | - | - |
| American Society For Experimental Neurotherapeutics | Direttore/Membro del Consiglio | - | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Direttore/Membro del Consiglio | 07/08/2014 | - |
Storia della carriera di Gail Farfel
Precedenti posizioni note di Gail Farfel
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | 29/06/2023 | 30/12/2023 |
| Amministratore Delegato | 19/09/2022 | 30/12/2023 | |
| Presidente | 19/09/2022 | 30/12/2023 | |
| ZOGENIX, INC. | Corporate Officer/Principal | 01/06/2015 | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/12/2012 | 01/06/2015 |
| Consigliere Generale | 01/12/2012 | 01/06/2015 | |
| G Meredith Consulting LLC | Presidente | 01/05/2008 | 01/12/2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di Gail Farfel
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 13 |
| Canada | 3 |
| Regno Unito | 2 |
Posizioni
| Director/Board Member | 7 |
| Corporate Officer/Principal | 4 |
| President | 2 |
Settori
| Health Technology | 11 |
| Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
| American Society For Experimental Neurotherapeutics |
- Borsa valori
- Insiders
- Gail Farfel
- Esperienza